[Cancer of the prostate: new hormone therapies].
Beside orchiectomy and estrogens, other endocrine manipulations are proposed for metastatic prostatic cancer patients. Antiandrogens, Cyproterone acetate and Flutamide, are often less efficient but less toxic than DES. Progestational agents medroxyprogesterone acetate, megoestrol acetate, chlormadinone acetate have also a limited activity. Inversely, tamoxifen is very little active. Preliminary results of ketoconazole need more controls. The present aims are to obtain, particularly by hormonal association, a more efficient and less toxic treatment, when DES can be given initially or becomes inefficient.
D000726:Androgen Antagonists / Q000627:therapeutic use*; D003534:Cyproterone / Q000627:therapeutic use; D005485:Flutamide / Q000627:therapeutic use; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use*; D008297:Male; D008525:Medroxyprogesterone / Q000627:therapeutic use; D008535:Megestrol / Q000627:therapeutic use; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy*; D011372:Progestins / Q000627:therapeutic use*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013629:Tamoxifen / Q000627:therapeutic use
D000726:Androgen Antagonists; D011372:Progestins; D013629:Tamoxifen; D005485:Flutamide; D003534:Cyproterone; D008535:Megestrol; D008525:Medroxyprogesterone; D007654:Ketoconazole
Cancer de la prostate: nouvelles hormonothérapies.